R. Klingenberg

Discipline

Psychologie (3) Economies et finances (1)

Type de document

Articles (18)

Co-auteur

Date

Source

Mot-clé

Patients (16) Patients (16) Syndromes (15) cohorte (14) risque (12) Risk (12) Human beings (12) Year (10) Ci (Chinese poetry) (10) Myocardial infarction (9) Older people (8) temps (durée) (7) mortalité (7) âge (7) Mortality (7) Time (7) Mortality (7) Cerebrovascular disease (7) Age (7) Age (7) association (6) Treatment (6) Death (6) Rates (6) Social groups (6) Death (6) Biochemical markers (6) Angiography (6) Rates (6) Risk factors (6)

Documents écrit par R. Klingenberg (18) | parle de R. Klingenberg (0)

History of peripheral artery disease and cardiovascular risk of real-world patients with acute coronary syndrome: Role of inflammation and comorbidities.
A. Denegri et al. (1 juil. 2023)
Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome.
L. Clement et al. (1 janv. 2023)
Smoking cessation and depression after acute coronary syndrome.
K. Krasieva et al.
Long-term effects of systematic smoking cessation counselling during acute coronary syndrome, a multicentre before-after study.
L. Gilgien-Dénéréaz et al. (18 juil. 2022)
Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) 2.0 Risk Score in Patients With Acute Coronary Syndromes.
R. Klingenberg et al. (19 oct. 2021)
CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients.
T. Mahendiran et al.
Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events.
R. Klingenberg et al.
Optimal Timing of Invasive Coronary Angiography following NSTEMI.
T. Mahendiran et al. (2020)
Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.
P. Winzap et al. (31 oct. 2019)
Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes.
N. Vuilleumier et al. (9 juil. 2019)
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention.
D. Carballo et al. (2019)
Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.
K.C. Koskinas et al. (13 avr. 2018)
Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.
S. Canivell et al. (2018)
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
B. Gencer et al. (9 nov. 2017)
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
R. Laaksonen et al. (1 juil. 2016)
Health utility indexes in patients with acute coronary syndromes.
B. Gencer et al. (2016)
Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
D. Nanchen et al. (2015)
Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications.
R. Auer et al. (2014)